Prostate Cancer Clinical Trial
Official title:
An Open, Single Dose, Antitumour Effect Study of 2-hydroxy-flutamide as a Controlled Release Product (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer
Verified date | March 2016 |
Source | Lidds AB |
Contact | n/a |
Is FDA regulated | No |
Health authority | Sweden: Medical Products Agency |
Study type | Interventional |
The primary aim of the study was to characterize and quantify the histopathological changes in the surgical specimens obtained in patients undergoing prostatectomy in addition to imaging changes (MRI) following a single injection of Liproca Depot in patients with localized prostate cancer.
Status | Completed |
Enrollment | 23 |
Est. completion date | May 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 50 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Age = 50 years, = 75 years 2. Histologically confirmed localized (stage T1c, T2a-T2c) prostate cancer that is judged relevant for prostatectomy. 3. PSA value < 20 ng/ml within 6 weeks before enrolment. 4. Gleason score = 3+4 at diagnostic biopsy (or preferably with more precise method for judging the localization of the primary tumour focus (foci). 5. Adequate renal function: Creatinine < 1.5 times upper limit of normal. 6. Adequate hepatic function: Aspartate Transaminase (ASAT), Alanine Transaminase (ALAT) and Alkalase Phosphatase (ALP) < 1.5 times upper limit of normal. 7. Negative dipstick for bacteriuria. 8. Patient must have ability to cope with the study procedures and to return to scheduled visits including follow up visit. 9. Patients that has been scheduled for prostatectomy Exclusion Criteria: 1. Ongoing or previous hormone therapy for prostate cancer. 2. On-going or previous therapy within 12 month of finasteride or dutasteride. 3. On-going or previous invasive therapy for benign prostate hyperplasia (TURP, TUMT). 4. Use of pace maker or other electronic devices 5. Symptoms or signs of acute prostatitis. 6. Symptoms or signs of ulcered proctitis 7. Severe micturation symptoms 8. On-going therapy with anticoagulant (e.g Warfarin. Other anticoagulant should be withdrawn 1 week before injection). 9. Concomitant systemic treatment with corticosteroids, or immune modulating agents. 10. Known immunosuppressive disease (e.g. HIV, diabetes). 11. Simultaneous participation in any other study involving not market authorized drugs or having participated in a study within the last 12 months prior to start of study treatment. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Finland | Dept of Urology, University Hospital | Tampere | |
Sweden | Dept of Urology, University Hospital | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Lidds AB | Uppsala University |
Finland, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Characterization and quantification of histopathological measurement of tumour tissue obtained from diagnostic biopsy. | Day 1 | No | |
Primary | Characterization and quantification of histopathological measurement of tumour tissue in surgical specimens obtained from patients undergoing prostatectomy | Six weeks | No | |
Primary | The diffusion/flow of tissue water (ADC) before and after treatment assessed by diffusion-weighted imaging (MRI) | Six weeks | No | |
Secondary | Concentration of Choline, Creatinine and Citrate in tumour tissue before and after treatment | Six weeks | No | |
Secondary | Surface fraction and volume of treated tumour focus (foci) based on MRI and histopathological map from surgical specimens at baseline and end of study, respectively | Six weeks | No | |
Secondary | Concentration of Plasma Prostate Specific Antigen (PSA) | Six weeks | No | |
Secondary | Total prostate volume by histopathology/MRI measúrements | Six weeks | No | |
Secondary | Number of participants with Adverse Events as a measure of Safety and Tolerability | Six weeks | Yes | |
Secondary | Number of abnormal, clinically relevant, parameters from laboratory analyses | Six weeks | Yes | |
Secondary | Pharmacokinetics (Tmax and Cmax) of 2-hydroxyflutamide (2-HOF) | Six weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |